NYSE:BMY
$24.33
(2/9 3:26PM)
+1.5%
| Open | $24.1 |
Mkt Cap | $47.5 Billion |
| High | $24.86 |
52Wk High | $26.62 |
| Low | $23.9 |
52Wk Low | $17.23 |
| Volume | 7.5 Million |
Avg Vol 10D | 13.9 Million |
Ockham's Rating/Recommendation Summary
Rating specific information requires Premium Access.
Buy Now
or
Learn More about Ockham's Features and Services.
BMY Revenue
For a long time, value investors have used the current share price relative to sales per share levels as an important valuation tool. We utilize a historical weighted average methodology that treats recent years more importantly in the calculation. When looking at BMY through this framework, we can see that our weighted average historical high and low Price to Sales per share ratios over the last 10 years are 3.34x and 2.28x respectively.
Utilizing this range we can see that BMY’s current Price to Sales per share ratio of 2.53x is below its historical average only slightly. So, while not a huge positive for our analysis, we do feel it is worth noting that BMY does look a bit undervalued on a Price to Sales basis, all other factors being equal. However, if the Price to Sales ratio drops further, Ockham Research is likely to become more bullish on this stock.
BMY Cash Earnings
Looking at BMY specifically in their Cash Earnings capabilities, Ockham views BMY as significantly below its historical average multiple of cash earnings as calculated by Ockham. Similar to our analysis of sales per share, Ockham looks at the last 10 years of cash earnings levels for BMY to identify where the current high and low price levels have been historically in relation to profit per share. Again, we utilize a weighted average methodology which relies more heavily on recent years of data. This weighted average framework provides us with an average high Price to Cash Earnings ratio per share of 17.51 and a 12.06 low over the same period.
Now that BMY’s current price is $23.97 and its Price to Cash Earnings ratio is 8.72, we are very positive on its outlook from the cash earnings perspective. In fact, BMY is now trading a full 42% below its average historical Price to Cash Earnings ratio at these profit per share levels. When our clients ask us why BMY has great long term potential, the Cash Earnings levels to current stock is one of our primary reasons. But naturally, now we need for the overall market to recognize this disparity.
BMY Dividends
When determining a company's future prospects for success, Ockham Research sees analysis of dividend payments as a key additional factor. Even though it isn't imperative for BMY to shell out a dividend in order to receive a positive rating, it can be helpful to further our analysis.
The estimated annual dividend for BMY is $1.28 producing a current dividend yield of 5.34%. Much like our evaluation of Sales and Cash Earnings per share, we review dividend yields from BMY against the historic high and low levels over all available dividend history. Because dividends are a decision made exclusively by management, we view a healthy and rising dividend as a sign of confidence and strength. The highest dividend yield from BMY over previous years was 7.73% while the lowest dividend yield was 1.18%. If you are looking for some “bang for your buck” then a dividend yield of 19.87% above the historical median should be enticing. BMY receives a positive boost in our view because as you know, equity at its core is simply a claim on future dividends.
Mad Money: Topics Include Emerging Markets and BMY
For growth, there is nowhere growing more rapidly than emerging markets. Recently, Mad Money talked about emerging markets and their impact on Bristol-Myers Squibb Company.
Based on our methodology, Bristol-Myers Squibb Company should hold some appeal to value investors as we view it as Undervalued. Crowd sentiment is leaning to the bearish side, according to the robust data set collected by the Motley Fool CAPS survey. We noticed recently that in comparison to all other stocks we analyze in the news; BMY has received less coverage from the financial media in business television and blogs.
“… BRISTOL MYERS had a terrific quarter. But the unsupported president who seems to think what's good for wall street is the enemy of your 401(k) and 529 -- nothing could be ... …”
Mad Money Discussed Dividends and BMY
If BMY's dividends are important to you, take a look at the news as they were the topic of conversation on Mad Money.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BMY has been less covered in the news compared to the rest of our universe of stocks. We consider BMY as Undervalued at the current price of $24.65. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise. The Motley Fool CAPS data suggests that investors believe Bristol-Myers Squibb Company will beat the market in the foreseeable future.
“… That's like BRISTOL MYERS, 5% yield, which my charitable trust owns. We like wellpoint, the least affected by washington. …”
Squawk Box Discussed the Latest Development of Bristol-Myers Squibb Company
News has broken via the television and viral blogs regarding BMY, so investors should take an interest in learning what was said.
When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Bristol-Myers Squibb Company has actually sunk a bit in comparison to the others. At present, Ockham has a valuation stance of Undervalued on BMY, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue. Crowd sentiment is favorable on this stock, as measured by the Motley Fool CAPS survey.
“… The way smee johnson was spun off by BRISTOL MYERS. Then they have the pipeline business which takes and connects all those arteries that bring natural gas to the northeast. …”
A Discussion of BMY's CEO Occurred on Street Signs
Ockham is always interested to know what the Chief Executive is doing for their company, and we noticed a mention of BMY's CEO on Street Signs.
Based on our methodology, Bristol-Myers Squibb Company should hold some appeal to value investors as we view it as Undervalued. Crowd sentiment is leaning to the bearish side, according to the robust data set collected by the Motley Fool CAPS survey. We noticed recently that in comparison to all other stocks we analyze in the news; BMY has received less coverage from the financial media in business television and blogs.
“… did you see the confusion over BRISTOL MYERS today. > > that was odd. Immediately the headline came out they cut forecasts. …”
Dividends and Bristol-Myers Squibb Company Among the Topics Covered on Mad Money
For income investors, dividend news is obviously important. BMY's dividends were discussed recently on Mad Money.
When looking at our entire coverage universe and ranking stocks by the attention they receive on RazorWire, it is clear that Bristol-Myers Squibb Company has been talked about more than normal recently. We consider BMY as Undervalued at the current price of $25.11. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise. The Motley Fool CAPS data suggests that investors believe Bristol-Myers Squibb Company will beat the market in the foreseeable future.
“… BRISTOL MYERS squib. > > do you keep the bristol-myers? It's got a good yield, it's got -- he's right down the road. He's one of the great ceos. You are welcome. …”
Power Lunch Discusses Higher Prices and Bristol-Myers Squibb Company
An abnormally high price is obviously a joyous occasion for investors in that stock. See what Power Lunch was talking about for BMY below.
Based on our methodology, Bristol-Myers Squibb Company should hold some appeal to value investors as we view it as Undervalued. Ranking all stocks in terms of news coverage offers some interesting data. In the case of BMY, it is getting significantly more attention in recent news coverage than we are used to seeing. Crowd sentiment is leaning to the bearish side, according to the robust data set collected by the Motley Fool CAPS survey.
“… tiffany's, BRISTOL-MYERS SQUIBB, forest labs all hitting 52-week highs today. Tiffany higher 43%. > > they're saying luxury is one area that will do well this > > …”
Check Out Closing Bell and News on BMY
News has broken via the television and viral blogs regarding BMY, so investors should take an interest in learning what was said.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, BMY has been less covered in the news compared to the rest of our universe of stocks. We consider BMY as Undervalued at the current price of $24.30. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise. The Motley Fool CAPS data suggests that investors believe Bristol-Myers Squibb Company will beat the market in the foreseeable future.
“… baby formula maker mead johnson focusing on BRISTOL-MYERS SQUIBB. Take a look at the stock night. You will see mixed perform answers there. > > > …”
Bristol-Myers Squibb Company Crosses Extremely Active News Threshold for the Day, Now on Squawk Box
If you own BMY, then you need to get to a TV now. It has been mentioned in the news very frequently in the last hour.
We noticed recently that in comparison to all other stocks we analyze in the news; BMY has received less coverage from the financial media in business television and blogs. Based on our methodology, Bristol-Myers Squibb Company should hold some appeal to value investors as we view it as Undervalued. Crowd sentiment is leaning to the bearish side, according to the robust data set collected by the Motley Fool CAPS survey.
“… BRISTOL MYERS planning to . …”
Interested in BMY? See What the Pundits Said on Squawk On The Street
The latest news from business television and influential blogs is always available through Ockham's RazorWire, and this news is in relation to Bristol-Myers Squibb Company.
Sent tweets. Is messages are often about drug study results, links to press releases or frivolous like pictures from a charity event. Others like BRISTOL-MYERS SQUIBB has created a twitter account but have yet to say anything. No company that i'm aware of is directly promoting a product on to figure out if or how that might eventually happen, today they start a two-day public hearing on pharma and social once a marketing director for
“… is directly promoting a product on to figure out if or how that might eventually happen, today they start a two-day public hearing on pharma and social once a marketing director for …”
See More News on BMY from Mad Money
Bristol-Myers Squibb Company is one of the thousands of companies that use news analytics on, and it was recently discussed on Mad Money.
Bank stock is ready to roar. Bp has a 20% move in the last few days, the last few weeks. A great yielder, great oil BRISTOL MYERS also has growth. I like that. Kinder morgan, terrific year. Flower, that's a food company. Is kinder morgan the same as bp? The answer is no. This is a transport company and this is integrated oil. They're not the same. This is like a toll road and this is like a prospector. I think he's got great horse i'm saying yes to all of our
“… he answer is no. This is a transport company and this is integrated oil. They're not the same. This is like a toll road and this is like a prospector. I think he's got great horse i'm saying yes to all of our …”